The Schizophrenia Program, Massachusetts General Hospital and Harvard Medical School, USA.
Pharmacol Biochem Behav. 2011 Aug;99(2):245-53. doi: 10.1016/j.pbb.2010.11.009. Epub 2010 Nov 27.
Cognitive deficits are major contributors to disability in schizophrenia. Many pharmacologic targets have been identified for cognitive enhancing agents, including receptors involved in dopaminergic, glutamatergic, GABAergic, serotonergic and cholinergic neurotransmission. In addition, new approaches to drug development have been directed towards neuroprotection and the facilitation of neuroplasticity. While several pharmacologic agents and cognitive remediation have shown promise in early trials, no treatment has yet demonstrated efficacy in large replication trials. The experience with different pharmacologic targets is reviewed and methodologic issues are discussed with recommendations for future research.
认知缺陷是精神分裂症致残的主要原因。许多用于认知增强的药物靶点已被确定，包括涉及多巴胺能、谷氨酸能、γ-氨基丁酸能、5-羟色胺能和胆碱能神经递质的受体。此外，药物开发的新方法还针对神经保护和促进神经可塑性。虽然几种药物和认知矫正在早期试验中显示出希望，但没有一种治疗方法在大型复制试验中显示出疗效。本文回顾了不同药物靶点的经验，并讨论了方法学问题，为未来的研究提出了建议。
